English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)
Post-registrative

Akynzeo

NEPA as antiemetic prophylaxis after failure of 5HT(3)-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience.
Autori:Valerio MR, Gebbia V, Borsellino N, Vecchia M, Serretta V, Pardo S, Cipolla C, Galanti D.
Fonte:J Oncol Pharm Pract. 2020 Jun 6:1078155220929409.
Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience.
Autori:Zilioli VR, Muzi C, Minga P, Codega P, Crucitti L, Meli E, Esposito A, Panico C, Rusconi C, Cairoli R.
Fonte:Int J Hematol Oncol. 2020 Feb 28;9(1):IJH23.
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study.
Autori:Di Renzo N, Musso M, Scimè R, Cupri A, Perrone T, De Risi C, Pastore D, Guarini A, Mengarelli A, Benedetti F, Mazza P, Capria V, Chiusolo P, Cupelli L, Federico V, Bozzoli V, Messa AR, Codega P, Bonizzoni E, Specchia G.
Fonte:Bone Marrow Transplant. 2020 Apr 28.
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study
Autori:Caputo R, Cazzaniga ME, Sbrana A, Torrisi R, Paris I, Giordano M, Montesarchio V, Guarneri V, Amaducci L, Bilancia D, Cilenti G, Fabi A, Collovà E, Schirone A, Bonizzoni E, Celio L, De Placido S, De Laurentiis M.
Fonte:BMC Cancer. 2020 Mar 19;20(1):232.
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients
Autori:Giuseppe Badalamenti, Lorena Incorvaia, Carlo Messina, Emmanuela Musso, Alessandra Casarin, Maria Rita Ricciardi, Ida De Luca, Viviana Bazan, Antonio Russo
Fonte:Support Care Cancer 2019 - 27 (9), 3593-3597
Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy.
Autori:Restelli U, Saibene G, Nardulli P, Di Turi R, Bonizzoni E, Scolari F, Perrone T, Croce D, Celio L.
Fonte:BMJ Open. 2017 Aug 1;7(7):e015645.

Aloxi

Every-other-day Palonosetron Plus Aprepitant for Prevention of Emesis Following Induction Chemotherapy for Acute Myeloid Leukemia: A Randomized, Controlled Study From the "Rete Ematologica Pugliese"
Autori:Nicola Di Renzo, Lorella Melillo, Fernando Porretto, Michela Dargenio, Vincenzo Pavone, Domenico Pastore, Patrizio Mazza, Donato Mannina, Anxur Merenda, Nicola Cascavilla, Giuseppina Greco, Rosella Matera, Erminio Bonizzoni, Luigi Celio, Maurizio Musso
Fonte:Cancer Med Jan 2020 9 (1), 170-178
Impact of Dexamethasone-Sparing Regimens on Delayed Nausea Caused by Moderately or Highly Emetogenic Chemotherapy: A Meta-Analysis of Randomised Evidence
Autori:Luigi Celio, Erminio Bonizzoni, Emma Zattarin, Paolo Codega, Filippo de Braud, Matti Aapro
Fonte:BMC Cancer 2019 Dec 30 19 (1), 1268
Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies.
Autori:Celio L, Bonizzoni E, De Braud F, Agustoni F, Aapro M.
Fonte:Support Care Cancer. 2016 Mar;24(3):1025-34.
Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.
Autori:Meattini I, Francolini G, Scotti V, De Luca Cardillo C, Cappelli S, Meacci F, Furfaro IF, Muntoni C, Scoccianti S, Detti B, Mangoni M, Nori J, Orzalesi L, Fambrini M, Bianchi S, Livi L.
Fonte:Med Oncol. 2015 Mar;32(3):80.
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Autori:Mirabile A, Celio L, Magni M, Bonizzoni E, Gianni AM, Di Nicola M.
Fonte:Future Oncol. 2014 Dec;10(16):2569-78. doi: 10.2217/fon.14.132
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study.
Autori:De Tursi M, Carella C, Tomao S, Cinieri S, Lorusso V, Marchetti P, Vecchio S, Sansoni E, Contu A, Adamo V, Silvestris N, Nuzzo A, Rosti G, Ravaioli A, Danova M, Tonini G, Passalacqua R, Cruciani G, Faedi M, Spada M, De Laurentiis M, Amoroso D, Tomao F, Sperduti I, Grassadonia A, Tinari N, Natoli C, Iacobelli S; Consorzio Interuniversitario Nazionale per la Bio-Oncologia.
Fonte:Tumori. 2014 Nov-Dec;100(6):e309-13.
Aprepitant versus dexamethasone for delayed emesis: what is the role of the 5-hydroxytryptamine type 3 receptor antagonist palonosetron.
Autori:Celio L, de Braud F, Aapro M.
Fonte:J Clin Oncol. 2014 Jul 10;32(20):2185-6.
Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.
Autori:Celio L, Agustoni F, Ricchini F, Dotti K, Niger M, Braud FD.
Fonte:Future Oncol. 2013 Oct;9(10):1451-8.
Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
Autori:Pacetti U, Veltri E, Fattoruso SI, Cardillo FD, Evangelista S, Cognetti F, Fabi A.
Fonte:Anticancer Res. 2013 Apr;33(4):1721-4.

Dropaxin

Depressive syndrome in perimenopausal, menopausal and postmenopausal patients. An Italian multicentre observational study.
Autori:Anniverno R, Gadler E, Poli R, Bellomo A, Ventriglio A, Pacilli AM, Barbieri S, Salemi O, Bondi E, Farina A, Mencacci C.
Fonte:Journal Of Psychopathology 2017;23:19-25
Efficacy and tolerability of paroxetine hydrocloride solution: slow titration vs standard titration.
Autori:Callegari C, Ielmini M, Bianchi L, Lucano M, Isella C, Bertù L, Vender S.
Fonte:European Journal of Biomedical and Pharmaceutical sciences. 2016;3(4):9-13.
Benefit of slow titration of paroxetine to treat depression in the elderly.
Autori:Olgiati P, Bajo E, Serretti A; C.E.A.P (Cost-Effectiveness Analysis on Psychiatric Disorders) Group.
Fonte:Hum Psychopharmacol. 2014 Nov;29(6):544-51.
Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
Autori:Gibiino S, Mori E, De Ronchi D, Serretti A.
Fonte:J Clin Psychopharmacol. 2013 Aug;33(4):565-9.
Paroxetine drops versus paroxetine tablets: evaluation of compliance in a six-month study.
Autori:Zanardi R, Colombo L, Marcheggiani E, Rossini D, Delmonte D, Cigala Fulgosi M, Gavinelli C, Colombo C.
Fonte:Riv Psichiatr. 2013 May-Jun;48(3):261-7.
Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study.
Autori:Amodeo L, Castelli L, Leombruni P, Cipriani D, Biancofiore A, Torta R.
Fonte:Support Care Cancer. 2012 Feb;20(2):375-84.
Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial.
Autori:Buoli M, Dell'osso B, Bosi MF, Altamura C.
Fonte:Psychiatry Clin Neurosci. 2010 Dec;64(6):612-9.

Endoprost

Intra-Arterial Administration of Iloprost in Patients Undergoing Endovascular or Hybrid Revascularization Procedures for Peripheral Arterial Disease.
Autori:Benedetto F, La Corte F, Spinelli D, Derone G, Cutrupi A, Varrà A, Barillà C
Fonte:Ann Vasc Surg. 2020 May; 16:S0890-5096
The Prostacyclin Analogue Iloprost as an Early Predictor of Successful Revascularization in Diabetic Patients Affected by Critical Limb Ischemia and Foot Ulcers.
Autori:Izzo V, Meloni M, Giurato L, Uccioli L.
Fonte:Cardiov Rev Med. 2019; 20:594-597.
Prostanoids for Critical Limb Ischemia: A Clinical Review and Consideration of Current Guideline Recommendations.
Autori:Meini S, Dentali F, Melillo E, de Donato G, Mumoli N, Mazzone A.
Fonte:Angiology. 2020 Mar;71(3):226-234.
Intra-arterial injection of iloprost reduces the risk of early recoil after balloon angioplasty of below-the-knee vessels in patients with critical limb ischemia.
Autori:Troisi N, Farina A, Chisci E, Ercolini L, Frosini P, Pigozzi C, Guidotti A, Michelagnoli S.
Fonte:J Cardiovasc Surg (Torino). 2019 ;60:718-722.
Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Autori:Foti R, Visalli E, Amato G, Benenati A, Converso G, Farina A, Bellofiore S, Mulè M, Di Gangi M.
Fonte:Rheumatol Int. 2017 Feb;37(2):245-249.
Behind guidelines: long term survival of critical limb ischemia patients treated with iloprost
Autori:Di Stefano R, Nuti M, Farina A, Meini S, Melillo E.
Fonte:European Heart Journal ( 2017 ) 38 ( Supplement ), 1278
Treatment with intravenous iloprost in patients with systemic sclerosis: a short review.
Autori:Visalli E, Amato G, Gangi MD, Benenati A, Cino N, Gagliano C, Falsaperla R, Farina A, Foti R.
Fonte:J Rare Dis Res Treat 2017;2(4):6-13.
Acute effect of iloprost on peripheral circulation as assessed by videocapillaroscopy and 22-mhz power doppler ultrasonography.
Autori:Schioppo T, Orenti A, Boracchi P, De Lucia O, Murgo A, Meroni PL, Ingegnoli F.
Fonte:Annals of the Rheumatic Diseases 2017;76:643.
A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
Autori:Fraticelli P, Martino GP, Murri M, Mattioli M, Gabrielli A.
Fonte:Clin Exp Rheumatol. 2017 Aug 31. [Epub ahead of print]
Efficacy, safety and feasibility of intravenous iloprost in the domiciliary treatment of patients with ischemic disease of the lower limbs
Autori:Polignano R, Baggiore C, Falciani F, Restelli U, Troisi N, Michelagnoli S, Panigada G, Tatini S, Farina A, Landini G.
Fonte:Eur Rev Med Pharmacol Sci 2016; 20 (17): 3720-6
Long-term survival of patients with critical limb ischemia treated with iloprost: response rate and predictive criteria. A retrospective analysis of 102 patients.
Autori:Melillo E, Lucaccini E, Berchiolli R, Adami D, Nuti M, Dell'Omo G, Farina A, Panigada G, Roberts AT, Meini S.
Fonte:Eur Rev Med Pharmacol Sci. 2016 Dec;20(24):5233-5241.
Long-term clinical outcomes in critical limb ischemia--A retrospective study of 181 patients.
Autori:Melillo E, Micheletti L, Nuti M, Dell'Omo G, Berchiolli R, Adami D, Farina A, Panigada G, Meini S.
Fonte:Eur Rev Med Pharmacol Sci. 2016;20(3):502-8.
Intra-arterial injection of iloprost reduces the risk of early recoil after balloon angioplasty of below-the-knee vessels in patients with critical limb ischemia.
Autori:Troisi N, Farina A, Chisci E, Ercolini L, Frosini P, Pigozzi C, Guidotti A, Michelagnoli S.
Fonte:J Cardiovasc Surg (Torino). 2016 Oct 4. [Epub ahead of print]
Treatment of Scleroderma-Related Digital Ulcers with Iloprost: A Cohort Study.
Autori:Colaci M, Lumetti F, Giuggioli D, Guiducci S, Ballando Randone S, Fiori G, Matucci-Cerinic M, Ferri C.
Fonte:Annals of the Rheumatic Diseases 2016;75:1117.
Iloprost (ILO) in Systemic Sclerosis (SSC): The Safety Experience of Two Italian Centres.
Autori:Guiducci S, Bellando-Randone S, Bruni C, Giuggioli D, Colaci M, Lumetti F, Lepri G, Fiori G, Bartoli F, Ferri C, Matucci-Cerinic M.
Fonte:Annals of the Rheumatic Diseases 2016;75:1122.
User preference for a portable syringe pump for iloprost infusion.
Autori:Laria A, Lurati AM, Re KA, Marrazza MG, Mazzocchi D, Farina A, Scarpellini M.
Fonte:Patient Relat Outcome Meas. 2015 May 19;6:139-44.
Organizational Impact of the Introduction of a New Portable Syringe Pump for Iloprost Therapy in Italian Hospital Settings
Autori:Restelli U, Faggioli P, Scolari F, Gussoni G, Valerio A, Sciascera A, Croce A, Mazzone A.
Fonte:Current Drug Therapy, 2015, 10, 105-112 105
Effects of iloprost on pain-free walking distance and clinical outcome in patients with severe stage IIb peripheral arterial disease: the FADOI 2bPILOT Study.
Autori:Mazzone A, Di Salvo M, Mazzuca S, Valerio A, Gussoni G, Bonizzoni E, Campanini M, Vescovo G, Nozzoli C; FADOI 2bPILOT Study Group.
Fonte:Eur J Clin Invest. 2013 Nov;43(11):1163-70.
Iloprost infusion by a new device as a portable syringe pump: safety, tolerability and agreement.
Autori:Faggioli P, Sciascera A, Giani L, Mazzone A.
Fonte:Italian Journal of Medicine (2012) 6, 311-14.
Acute limb ischemia in elderly patients: can iloprost be useful as an adjuvant to surgery? Results from the ILAILL study.
Autori:de Donato G, Gussoni G, de Donato G, Cao P, Setacci C, Pratesi C, Mazzone A, Ferrari M, Veglia F, Bonizzoni E, Settembrini P, Ebner H, Martino A, Palombo D; Ilaill Study Group.
Fonte:Eur J Vasc Endovasc Surg. 2007 Aug;34(2):194-8.
The ILAILL study: iloprost as adjuvant to surgery for acute ischemia of lower limbs: a randomized, placebo-controlled, double-blind study by the italian society for vascular and endovascular surgery.
Autori:de Donato G, Gussoni G, de Donato G, Andreozzi GM, Bonizzoni E, Mazzone A, Odero A, Paroni G, Setacci C, Settembrini P, Veglia F, Martini R, Setacci F, Palombo D.
Fonte:Ann Surg. 2006 Aug;244(2):185-93.

Fentalgon

Pharmacokinetic study between a bilayer matrix fentalyl patch and a monolayer matrix fentanyl patch: single dose administration in healthy volunteers.
Autori:Zecca E, Manzoni A, Centurioni F, Farina A, Bonizzoni E, Seiler D, Perrone T, Caraceni A.
Fonte:Br J Clin Pharmacol. 2015 Jul;80(1):110-5.

Ferplex Fol

Iron plus folate is more effective than iron alone in the treatment of iron deficiency anaemia in pregnancy: a randomised, double blind clinical trial.
Autori:Juarez-Vazquez J, Bonizzoni E, Scotti A.
Fonte:BJOG. 2002 Sep;109(9):1009-14.

Fripass

Cilostazol reduces dry eye symptoms and improve walking distance in patients with peripheral artery disease.
Autori:Chisari LM, Malaguarnera S, Grasso A, Malaguarnera M, Chisari G, Borzì AM, Chisari CG.
Fonte:Clin Ter. 2019 Sep-Oct;170(5):e357-e363. doi: 10.7417/CT.2019.2160.
Restenosis after Coronary and Peripheral Intervention: Efficacy and Clinical Impact of Cilostazol.
Autori:de Donato G, Setacci F, Mele M, Giannace G, Galzerano G, Setacci C.
Fonte:Ann Vasc Surg. 2017 May;41:300-307.
Patterns and determinants of use of pharmacological therapies for intermittent claudication in PAD outpatients: results of the IDOMENEO study.
Autori:Cimminiello C, Polo Friz H, Marano G, Arpaia G, Boracchi P, Spezzigu G, Visonà A; SIAPAV Investigators.
Fonte:Int Angiol. 2017 Jun;36(3):254-260.
The use of cilostazol in patients with peripheral arterial disease: results of a national physician survey.
Autori:de Donato G, Setacci F, Galzerano G, Mele M, Ruzzi U, Setacci C.
Fonte:J Cardiovasc Surg (Torino). 2016 Jun;57(3):457-65.
Efficacy of cilostazol for the treatment of Raynaud's phenomenon in systemic sclerosis patients.
Autori:Negrini S, Spanò F, Penza E, Rollando D, Indiveri F, Filaci G, Puppo F.
Fonte:Clin Exp Med. 2016 Aug;16(3):407-12.
A prospective multicentre study on the treatment of cardiovascular risk factors and claudication symptoms in patients with peripheral artery disease (the IDOMENEO study).
Autori:Cimminiello C, Arpaia G, Polo Friz H, Boracchi P, Marano G, Spezzigu G, Visonà A.
Fonte:Vasa. 2015 Sep;44(5):371-9.
New therapeutic effects of cilostazol in patients with ischemic disorders.
Autori:Biscetti F, Ferraccioli G, Flex A.
Fonte:Curr Vasc Pharmacol. 2015;13(3):399-404.
Cilostazol prevents foot ulcers in diabetic patients with peripheral vascular disease.
Autori:de Franciscis S, Gallelli L, Battaglia L, Molinari V, Montemurro R, Stillitano DM, Buffone G, Serra R.
Fonte:Int Wound J. 2015 Jun;12(3):250-3.
Restenosis: a challenge for vascular surgeon.
Autori:Setacci C, Castelli P, Chiesa R, Grego F, Simoni GA, Stella A, Galzerano G, Sirignano P, De Donato G, Setacci F.
Fonte:J Cardiovasc Surg (Torino). 2012 Dec;53(6):735-46

Gelistrol

Female sexuality and vaginal health across the menopausal age
Autori:Angelo Cagnacci, MD, PhD,1 Martina Venier, MD,1 Anjeza Xholli, MD,1 Chiara Paglietti, MD,1
Fonte:Salvatore Caruso, MD,2 for the ANGEL Study: Menopause: The Journal of The North American Menopause Society 2020 Vol. 27, No. 1, pp. 1-6
Lower urinary tract symptoms and their relation to vaginal atrophy in women across the menopausal age span. Results from the ANGEL multicentre observational study
Autori:Angelo Cagnaccia,*, Martina Sclauzerob, Cristina Meriggiolac, Anjeza Xhollia, for the ANGEL study:
Fonte:Maturitas 140 (2020) 8–13
Local ultra-low-dose estriol gel treatment of vulvovaginal atrophy: efficacy and safety of long-term treatment
Autori:Paola Villa, Valeria Tagliaferri, Inbal Dona Amar, Clelia Cipolla, FabioIngravalle, Giovanni Scambia, Walter Ricciardi & Antonio Lanzone:
Fonte:Gynecological Endocrinology 17 Dec 2019.
Vaginal atrophy across the menopausal age: results from the ANGEL study
Autori:A. Cagnacci, A. Xholli, M. Sclauzero, M. Venier, F. Palma, M. Gambacciani & writing group of the ANGEL study:
Fonte:CLIMACTERIC Published online 2 January 2019
The most bothersome symptom of vaginal atrophy: Evidence from the observational AGATA study
Autori:Federica Palmaa, Anjeza Xhollia, Angelo Cagnaccib, as the writing group of the AGATA study:
Fonte:Maturitas 2018;108:18–23
Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?
Autori:Maria Grazia Matarazzo*, Salvatore Caruso, Giuliana Giunta, Gaetano Valenti, Giuseppe Sarpietro, Antonio Cianci:
Fonte:European Journal of Obstetrics & Gynecology and Reproductive Biology 222 (2018) 75–79
Management of vaginal atrophy: a real mess. Results from the AGATA study
Autori:Federica Palma, Anjeza Xholli, Angelo Cagnacci & as the writing group of the AGATA study:
Fonte:Gynecol Endocrinol, 2017; 33(9): 702–707
Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse
Autori:Salvatore Caruso, MD,1,2 Stefano Cianci, MD,1 Salvatore Giovanni Vitale, MD,3Maria Grazia Matarazzo, MD,1 Francesca Flavia Amore, MD,4 and Antonio Cianci, MD1,2:
Fonte:Menopause: The Journal of The North American Menopause Society 2017;24,(8): 900-907
Prevalence and association between objective signs and subjective symptoms of vaginal atrophy: the AGATA study
Autori:Angelo Cagnacci, MD, PhD, Maria M. Carbone, MD, and Federica Palma, MD, for the AGATA study :
Fonte:Menopause- 2016; 23(10):1139-45.
Medical and patient attitude towards vaginal atrophy: the AGATA study
Autori:F. Palma, E. Della Vecchia, A. Cagnacci & as the Writing Group of the AGATAstudy:
Fonte:Climacteric, 2016
Vaginal atrophy of women in postmenopause. Results from amulticentric observational study: The AGATA study
Autori:F. Palmaa,∗, A. Volpea, P. Villab, A. Cagnaccia,∗, as the writing group of the AGATA study:
Fonte:Maturitas 2016; 83:40-44
Quality of life and sexual function of naturally postmenopausal womenon an ultralow-concentration estriol vaginal gel
Autori:Salvatore Caruso, MD,1 Stefano Cianci, MD,1 Francesca F. Amore, MD,2 Betty Ventura, MD,1Elisa Bambili, MD,1 Saveria Spadola, MD,2 and Antonio Cianci, MD1:
Fonte:Menopause. 2016; 23(1):47-54.
Coital pain in the elderly: could a low dose estriol gel thrill the vulvar vestibule?
Autori:Filippo Murinaa,*, Alessandra Graziottinb, Raffaele Felicea, Stefania Di Francescoa
Fonte:European Journal of Obstetrics & Gynecology and Reproductive Biology 207 (2016) 121–124
A comparison between vaginal estrogen and vaginal hyaluronic for thetreatment of dyspareunia in women using hormonal contraceptive
Autori:Maurizio Serati *, Giorgio Bogani, Maria Carmela Di Dedda, Alice Braghiroli,Stefano Uccella, Antonella Cromi, Fabio Ghezzi:
Fonte:European Journal of Obstetrics & Gynecology and Reproductive Biology 191 (2015) 48–50

Muphoran

Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas.
Autori:Minniti G, Agolli L, Falco T, Scaringi C, Lanzetta G, Caporello P, Osti MF, Esposito V, Enrici RM.
Fonte:J Neurooncol. 2015 May;122(3):559-66.
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Autori:Di Giacomo AM, Ascierto PA, Queirolo P, Pilla L, Ridolfi R, Santinami M, Testori A, Simeone E, Guidoboni M, Maurichi A, Orgiano L, Spadola G, Del Vecchio M, Danielli R, Calabrò L, Annesi D, Giannarelli D, Maccalli C, Fonsatti E, Parmiani G, Maio M.
Fonte:Ann Oncol. 2015 Apr;26(4):798-803.
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.
Autori:Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A.
Fonte:Biomed Res Int. 2014;2014:351252.
Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.
Autori:Nava F, Tramacere I, Fittipaldo A, Bruzzone MG, Dimeco F, Fariselli L, Finocchiaro G, Pollo B, Salmaggi A, Silvani A, Farinotti M, Filippini G.
Fonte:Neuro Oncol. 2014 May;16(5):719-27.
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
Autori:Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG, Pasqualetti F, Lolli I, Castiglione A, Ciccone G, Rudà R.
Fonte:J Neurooncol. 2014 Feb;116(3):533-41.

Myelostim

Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation.
Autori:Restelli U, Croce D, Bonizzoni E, Marzanatti M, Andreini A, Sorio M, Tecchio C, Barison E, Benedetti F.
Fonte:J Blood Med. 2020 Apr 2;11:123-130.
Lenograstim and filgrastim in the febrile neutropenia prophylaxis of hospitalized patients: efficacy and cost of the prophylaxis in a retrospective survey.
Autori:Innocenti R, Rigacci L, Restelli U, Scappini B, Gianfaldoni G, Fanci R, Mannelli F, Scolari F, Croce D, Bonizzoni E, Perrone T, Bosi A.
Fonte:J Blood Med. 2018 Dec 27;10:21-27.
Biosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience.
Autori:Marchesi F, Vacca M, Gumenyuk S, Pandolfi A, Renzi D, Palombi F, Pisani F, Romano A, Spadea A, Ipsevich F, Santinelli S, De Rienzo M, Papa E, Canfora M, Laurenzi L, Foddai ML, Pierelli L, Mengarelli A.
Fonte:Leuk Lymphoma. 2015 Jul 18:1-4. [Epub ahead of print].
Mobilization of hematopoietic stem cells with lenograstim in healthy donors: efficacy and safety analysis according to donor age.
Autori:Martino M, Bonizzoni E, Moscato T, Recchia AG, Fedele R, Gallo GA, Console G, Messina G, Morabito F.
Fonte:Biol Blood Marrow Transplant. 2015 May;21(5):881-8.
Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control.
Autori:Martino M, Moscato T, Barillà S, Dattola A, Pontari A, Fedele R, Furlò G, Marzia Stilo C, Alberto Gallo G, Tripepi G.
Fonte:Transfusion. 2015 Aug;55(8):2032-8.
Feasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.
Autori:Rigacci L, Puccini B, Kovalchuk S, Fabbri E, Bonizzoni E, Perrone T, Bosi A.
Fonte:Support Care Cancer. 2014 Sep;22(9):2557-61.
Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies.
Autori:Ria R, Reale A, Melaccio A, Racanelli V, Dammacco F, Vacca A.
Fonte:Clin Exp Med. 2015 May;15(2):145-50.
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization.
Autori:Orciuolo E, Buda G, Marturano E, Mauro E, Milone G, Cangialosi C, Di Renzo N, Pastore D, Specchia G, De Paolis MR, Mazza P, Pietrantuono G, Petrini M.
Fonte:Leuk Res. 2011 Jul;35(7):899-903.

Natecal

Intake di calcio in pazienti ambulatoriali con possibile osteoporosi: studio italiano multicentrico (siommms: Società Italiana dell'Osteoporosi del Metabolismo Minerale e delle Malattie dello Scheletro
Autori:Elisa Cairoli, Carmen Aresta, Luca Giovanelli, Cristina Eller-Vainicher, Silvia Migliaccio, Sandro Giannini, Andrea Giusti, Claudio Marcocci, Stefano Gonnelli, Giovanni Carlo Isaia, lacopo Chiodini, Marco Di Stefano
Fonte:Atti XIX Congresso Nazionale SIOMMMS - C15 – Sessione 3
Adherence to Calcium and Vitamin D supplementations: results from the ADVICE Survey.
Autori:Conti F, Piscitelli P, Italiano G, Parma A, Caffetti MC, Giolli L, Di Tanna GL, Guazzini A, Brandi ML.
Fonte:Clin Cases Miner Bone Metab. 2012 Sep;9(3):157-60. Epub 2012 Dec 20.

Seleparina

Low molecular weight heparin improves healing of chronic venous ulcers especially in the elderly.
Autori:Serra R, Buffone G, Molinari V, Montemurro R, Perri P, Stillitano DM, Amato B, de Franciscis S.
Fonte:Int Wound J. 2015 Apr;12(2):150-3.
The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?
Autori:Barni S, Bonizzoni E, Verso M, Gussoni G, Petrelli F, Perrone T, Agnelli G.
Fonte:Blood. 2014 Jul 3;124(1):155-6.
Update on distal deep venous thrombosis. Reports of a multicenter study.
Autori:Guarnera G, Abeni D, Antignani PL, Apollonio A, Conti F, Mollo PL, Murgiano A, Ofria F, Ruggeri M.
Fonte:Int Angiol. 2014 Dec;33(6):560-4.
Prophylaxis against venous thromboembolism in patients with cancer.
Autori:Verso M, Agnelli G.
Fonte:N Engl J Med. 2014 Sep 25;371(13):1262.
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.
Autori:Napolitano M, Saccullo G, Malato A, Sprini D, Ageno W, Imberti D, Mascheroni D, Bucherini E, Gallucci P, D'Alessio A, Prantera T, Spadaro P, Rotondo S, Di Micco P, Oriana V, Urbano O, Recchia F, Ghirarduzzi A, Lo Coco L, Mancuso S, Casuccio A, Rini GB, Siragusa S.
Fonte:J Clin Oncol. 2014 Nov 10;32(32):3607-12.
Low-molecular -weight heparin in pregnancies after ART -a retrospective study-.
Autori:Grandone E, Villani M, Dentali F, Tiscia GL, Colaizzo D, Cappucci F, Fischetti L, Ageno W, Margaglione M.
Fonte:Thromb Res. 2014 Aug;134(2):336-9. doi: 10.1016/j.thromres.2014.06.004. Epub 2014 Jun 11.
Clinical Pregnancies and Live Births in women approaching ART: a follow-up analysis of 157 women after thrombophilia screening.
Autori:Grandone E, Villani M, Tiscia GL, Dentali F, Colaizzo D, Cappucci F, Chinni E, Ageno W, Margaglione M.
Fonte:Thromb Res. 2014 Feb;133(2):168-72.
Clinical utility of antithrombotic prophylaxis in ART procedures: an Italian experience.
Autori:Grandone E, Villani M, Tiscia GL, Dentali F, Colaizzo D, Cappucci F, Fischetti L, Ageno W, Margaglione M.
Fonte:PLoS One. 2014 May 28;9(5):e97604.
News on distal deep venous thrombosis. Preliminary reports of a multicentre study
Autori:Guarnera G, Abeni D, Antignani PL, Apollonio A, Conti F, Mollo PL, Murgiano A, Ofria F, Ruggieri M.
Fonte:Acta Phlebologica 2012 August;13(2):105-8
A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.
Autori:Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R.
Fonte:Intern Emerg Med. 2012 Jun;7(3):291-2.
Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study.
Autori:Barni S, Labianca R, Agnelli G, Bonizzoni E, Verso M, Mandalà M, Brighenti M, Petrelli F, Bianchini C, Perrone T, Gasparini G.
Fonte:J Transl Med. 2011 Oct 20;9:179. doi: 10.1186/1479-5876-9-179.
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.
Autori:Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators.
Fonte:Lancet Oncol. 2009 Oct;10(10):943-9.

Teglutik

Dysphagia in Amyotrophic Lateral Sclerosis: Impact on Patient Behavior, Diet Adaptation, and Riluzole Management.
Autori:Onesti E, Schettino I, Gori MC, Frasca V, Ceccanti M, Cambieri C, Ruoppolo G, Inghilleri M.
Fonte:Front Neurol. 2017 Mar 21;8:94.
TEGLUTIK, A NOVEL LIQUID FORMULATION OF RILUZOLE FOR DYSPHAGIC ALS PATIENTS
Autori:Gonzalez J, Perrone T.
Fonte:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17:sup1, 236-263
BIOEQUIVALENCE STUDY OF TEGLUTIK, AN INNOVATIVE ORAL SUSPENSION OF RILUZOLE, PHARMACOKINETIC ANALYSIS IN HEALTHY VOLUNTEERS
Autori:Bettica P, Gonzalez J, Del Bene F, Germani M, Fiorentini F, Perrone T, Rocchetti.
Fonte:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17:sup1, 236-263
DYSPHAGIA IN AMYOTROPHIC LATERAL SCLEROSIS AND POSSIBLE IMPACT ON RILUZOLE MANAGEMENT
Autori:Inghilleri M, Onesti E, Schettino I, Gori MC, Frasca V, Cambieri C, Ceccanti M, Ruoppolo G.
Fonte:Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 17:sup1, 236-263

Vasexten

Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus.
Autori:Derosa G, Mugellini A, Pesce RM, D'Angelo A, Maffioli P.
Fonte:BMC Cardiovasc Disord. 2016 Apr 12;16:66. doi: 10.1186/s12872-016-0237-z.
Effect of bedtime dosing of barnidipine hydrochloride in non-dipper hypertensive patients with obstructive sleep apnoea not treated with continuous positive airway pressure.
Autori:Crippa G, Zabzuni D, Cassi A, Bravi E.
Fonte:Eur Rev Med Pharmacol Sci. 2016;20(2):339-44.
Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients.
Autori:Derosa G, Mugellini A, Pesce RM, D'Angelo A, Maffioli P.
Fonte:Eur J Pharmacol. 2015 Nov 5;766:31-6. doi: 10.1016/j.ejphar.2015.09.030. Epub 2015 Sep 25.
Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial.
Autori:Derosa G, Mugellini A, Querci F, Franzetti I, Pesce RM, D'Angelo A, Maffioli P.
Fonte:Sci Rep. 2015 Aug 5;5:12603. doi: 10.1038/srep12603.
Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus.
Autori:Derosa G, Querci F, Franzetti I, Dario Ragonesi P, D'Angelo A, Maffioli P.
Fonte:Hypertens Res. 2015 Oct;38(10):690-4.
Effects of barnidipine in comparison with hydrochlorothiazide on endothelial function, as assessed by flow mediated vasodilatation in hypertensive patients.
Autori:Muiesan ML, Salvetti M, Belotti E, Paini A, Rosei CA, Aggiusti C, Scotti A, de Ciuceis C, Rizzoni D, Rosei EA.
Fonte:Blood Press. 2011 Aug;20(4):244-51.
Effectiveness of barnidipine 10 or 20 mg plus losartan 50-mg combination versus losartan 100-mg monotherapy in patients with essential hypertension not controlled by losartan 50-mg monotherapy: A 12-week, multicenter, randomized, open-label, parallel-group study.
Autori:Parati G, Giglio A, Lonati L, Destro M, Ricci AR, Cagnoni F, Pini C, Venco A, Maresca AM, Monza M, Grandi AM, Omboni S.
Fonte:Clin Ther. 2010 Jul;32(7):1270-84.
Arterial wave reflection during antihypertensive therapy with barnidipine: a 6-month, open-label study using an integrated cardiovascular ultrasound approach in patients with newly diagnosed hypertension.
Autori:Palombo C, Malshi E, Morizzo C, Rakebrandt F, Corretti V, Santini F, Fraser AG, Kozakova M.
Fonte:Clin Ther. 2009 Dec;31(12):2873-85.
Effects of barnidipine on blood pressure and left ventricular diastolic function in patients with hypertension and metabolic syndrome: A 12-week, open-label noncomparison study.
Autori:Angeli F, Repaci S, Borgioni C, Sardone M, Scotti A, Verdecchia P.
Fonte:Curr Ther Res Clin Exp. 2008 Jun;69(3):207-20
Antihypertensive effect of barnidipine 10 mg or amlodipine 5 to 10 mg once daily in treatment-naive patients with essential hypertension: A 24-week, randomized, open-label, pilot study.
Autori:Rossetti G, Pizzocri S, Brasca F, Pozzi M, Beltrami LM, Bolla GB, Famiani R, Caimi B, Omboni S, Magrini F, Carugo S.
Fonte:Curr Ther Res Clin Exp. 2008 Jun;69(3):192-206. doi: 10.1016/j.curtheres.2008.06.002. Erratum in: Curr Ther Res Clin Exp. 2008 Aug;69(4):378-9.